Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
09 août 2021 14h39 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
26 févr. 2021 09h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides additional study details for...
Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
29 janv. 2021 09h15 HE
|
Innovation Pharmaceuticals Inc.
Brilacidin treatment unlikely to be impacted by coronavirus variants, such as those originating in the U.K., South Africa and Brazil, and spreading worldwide, due to its ability to attack the virus...
Cannabis Strategic Ventures Announces First Sales from NUGS FARM Cultivation, Manufacturing and Distribution Facility
10 sept. 2019 06h00 HE
|
Cannabis Strategic Ventures, Inc.
LOS ANGELES, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Los Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) is proud to announce the first round of product sales from the...